Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...

CRISPR is a powerful gene-editing tool that holds enormous potential for treating genetic diseases by allowing scientists to ...

Researchers at the Experimental and Clinical Research Center (ECRC), a joint institution of the Max Delbrück Center and ...

The core components of CRISPR-based genome-editing therapies are bacterial proteins called nucleases that can stimulate ...

Bengaluru-based biotechnology startup, CrisprBits Private Limited, has inaugurated a CRISPR gene editing and diagnostics ...

Analyst Gil Blum from Needham maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) and keeping the price target at ...

The new Express License service removes barriers to accessing this transformative gene editing technology for startups.An ...

Researchers at the Experimental and Clinical Research Center in Berlin are developing a targeted treatment for muscular ...

Treatments for rare diseases are hard to create and expensive to deliver, but there is new hope for editing the software of ...

It feels fantastic,” said Blau, who thanked her lab members and colleagues for their support and dedication. “This ...

BENGALURU, India, Jan. 16, 2025 /PRNewswire/ -- Bengaluru-based biotechnology startup, CrisprBits Private Limited, has inaugurated a CRISPR gene ... molecular biology research, and cleanroom ...